Verastem, Inc. has initiated the rolling submission of a New Drug Application (NDA) to the FDA for the combination of avutometinib and defactinib for the treatment of recurrent KRAS mutant low-grade serous ovarian cancer (LGSOC). The estimated market opportunity for this product candidate is approximately $300 million for KRAS mt and $270 million for KRAS wt populations.